المؤلفون: O. V. Vorob'eva, N. N. Shindryaeva, V. V. Fateeva, О. В. Воробьева, Н. Н. Шиндряева, В. В. Фатеева

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 3 (2024); 12-18 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 3 (2024); 12-18 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-3

مصطلحات موضوعية: long COVID, atrial fibrillation, vascular risk factors, фибрилляция предсердий, сосудистые факторы риска

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2273/1660; Остроумова ОД, Кочетков АИ, Остроумова ТМ. Фибрилляция предсердий и когнитивные нарушения: распространенность и патогенетические механизмы взаимосвязи (часть 1). Неврология, нейропсихиатрия, психосоматика. 2020;12(3):105-10. doi:10.14412/2074-27112020-3-105-110; Sachdev PS, Lipnicki DM, Kochan NA, et al. The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: the COSMIC collaboration. PLoS One. 2015;10(11):e0142388. doi:10.1371/journal.pone.0142388; Lopez OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2007;64(3):416-20. doi:10.1001/archneur.64.3.416; Крупенин ПМ, Воскресенская ОН, Напалков ДА и др. Когнитивные нарушения и болезнь мелких сосудов при фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):55-62. doi:10.14412/2074-2711-2022-6-55-62; Zuin M, Roncon L, Passaro A, et al. Risk of dementia in patients with atrial fibrillation: Short versus long follow-up. A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2021;36(10):1488-500. doi:10.1002/gps.5582 . Epub 2021 May 27.; Парфенов ВА. Когнитивные нарушения у пациентов с фибрилляцией предсердий. Consilium Medicum. 2023;25(2):81-5. doi:10.26442/20751753.2023.2.202220; WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int/ (accessed 04.03.2024).; Боголепова АН, Коваленко ЕА, Махнович ЕВ идр. Когнитивные нарушения после COVID-19: отдаленные последствия. Эффективная фармакотерапия. 2022;18(26):24-30. doi:10.33978/23073586-2022-18-26-24-30; Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258-63. doi:10.1016/j.cmi.2020.09.052. Epub 2020 Oct 5.; Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One. 2020 Dec 11;15(12):e0243882. doi:10.1371/journal.pone.0243882; Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428-42. doi:10.1177/01410768211032850. Epub 2021 Jul 15.; Terlecki M, Wojciechowska W, Klocek M, et al. Prevalence and clinical implications of atrial fibrillation in patients hospitalized due to COVID-19: Data from a registry in Poland. Front Cardiovasc Med. 2023 Mar 13:10:1133373. doi:10.3389/fcvm.2023.1133373. eCollection 2023.; Воробьева ОВ. Аффективные нарушения у пациентов с церебральной микроангиопатией в период пандемии COVID-19. РМЖ. 2021;(5):35-41.; El-Arif G, Farhat A, Khazaal S, et al. The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19. Molecules. 2021 Nov 17;26(22):6945. doi:10.3390/molecules26226945; Coto E, Avanzas P, Gomez J. The Renin-Angiotensin-Aldosterone System and Coronavirus Disease 2019. Eur Cardiol. 2021 Mar 9:16:e07. doi:10.15420/ecr.2020.30. eCollection 2021 Feb.; Scutelnic A, Heldner MR. Vascular Events, Vascular Disease and Vascular Risk Factors-Strongly Intertwined with COVID-19. Curr Treat Options Neurol. 2020;22(11):40. doi:10.1007/s11940-020-00648-y. Epub 2020 Oct 8.; Chung MK, Zidar DA, Bristow MR, et al. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res. 2021;128(8):1214-36. doi:10.1161/CIRCRESAHA.121.317997; Воробьева ОВ. Церебральная микроангиопатия, ассоциированная с артериальной гипертензией и метаболическими нарушениями. Эффективная фармакотерапия. 2020;3(20):62-9.; Крупенин ПМ, Перепелов ВА, Перепелова ЕМ идр. Компьютерный анализ данных магнитно-резонансной томографии головного мозга в верификации болезни мелких сосудов и умеренного когнитивного расстройства. Consilium Medicum. 2022;24(2):90-5. doi:10.26442/20751753.2022.2.201353; Owens CD, Pinto CB, Detwiler S, et al. Cerebral small vessel disease pathology in COVID-19 patients: A systematic review. Ageing Res Rev. 2023 Jul:88:101962. doi:10.1016/j.arr.2023.101962. Epub 2023 May 22.; Sachdev P, Kalaria R, O'Brien J, et al; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18. doi:10.1097/WAD.0000000000000034; Julayanont P, Brousseau M, Chertkow H, et al. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. J Am Geriatr Soc. 2014 Apr;62(4):679-84. doi:10.1111/jgs.12742. Epub 2014 Mar 17.; Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020 Apr 15;22(2):95-7. doi:10.51893/2020.2.pov2. Epub ahead of print.; Woo MS, Malsy J, Pottgen J, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020 Nov 23;2(2):fcaa205. doi:10.1093/brain-comms/fcaa205; Головачева ВА, Табеева ГР, Кузнецов ИВ. Когнитивные нарушения при COVID-19: взаимосвязь, патогенез и вопросы терапии. Неврология, нейропсихиатрия, психосоматика. 2021;13(2):123-9. doi:10.14412/2074-2711-2021-2-123-129; Moretta P, Ambrosino P, Lanzillo A, et al. Cognitive Impairment in Convalescent COVID-19 Patients Undergoing Multidisciplinary Rehabilitation: The Association with the Clinical and Functional Status. Healthcare (Basel). 2022 Mar 4;10(3):480. doi:10.3390/healthcare10030480; Palta P, Albert MS, Gottesman RF. Heart health meets cognitive health: evidence on the role of blood pressure. Lancet Neurol. 2021 Oct;20(10):854-67. doi:10.1016/S1474-4422(21)00248-9; https://nnp.ima-press.net/nnp/article/view/2273

الاتاحة: https://nnp.ima-press.net/nnp/article/view/2273
https://doi.org/10.14412/2074-2711-2024-3-12-18

المؤلفون: N. V. Pizova, A. V. Pizov, Н. В. Пизова, А. В. Пизов

المصدر: Meditsinskiy sovet = Medical Council; № 12 (2024); 31–38 ; Медицинский Совет; № 12 (2024); 31–38 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: холина альфосцерат, cerebrovascular diseases, vascular risk factors, cerebral small vessel disease, choline alfoscerate, цереброваскулярные заболевания, сосудистые факторы риска, церебральная болезнь мелких сосудов

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8466/7444; Sagaro GG, Traini E, Amenta F. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2023;92(1):59–70. https://doi.org/10.3233/jad-221189.; Crimmins EM, Kim JK, Langa KM, Weir DR. Assessment of cognition using surveys and neuropsychological assessment: the Health and Retirement Study and the Aging, Demographics, and Memory Study. J Gerontol B Psychol Sci Soc Sci. 2011;66(1 Suppl.):i162–171. https://doi.org/10.1093/geronb/gbr048.; Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5(12):e661–e671. https://doi.org/10.1016/S2468-2667(20)30185-7.; Nelson ME, Jester DJ, Petkus AJ, Andel R. Cognitive Reserve, Alzheimer’s Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis. Neuropsychol Rev. 2021;31(2):233–250. https://doi.org/10.1007/s11065-021-09478-4.; Chertkow H. Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. CMAJ. 2008;178(3):316–321. https://doi.org/10.1503/cmaj.070795.; Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry. 2006;189(5):399–404. https://doi.org/10.1192/bjp.bp.105.014779.; Roh JH, Lee JH. Recent updates on subcortical ischemic vascular dementia. J Stroke. 2014;16(1):18–26. https://doi.org/10.5853/jos.2014.16.1.18.; Parra MA, Butler S, McGeown WJ, Brown Nicholls LA, Robertson DJ. Globalising strategies to meet global challenges: the case of ageing and dementia. J Glob Health. 2019;9(2):020310. https://doi.org/10.7189/jogh.09.020310.; Ardelt M. Are Older Adults Wiser Than College Students? A Comparison of Two Age Cohorts. J Adult Dev. 2010;17:193–207. https://doi.org/10.1007/s10804-009-9088-5.; Park DC, Lautenschlager G, Hedden T, Davidson NS, Smith AD, Smith PK. Models of visuospatial and verbal memory across the adult life span. Psychol Aging. 2002;17(2):299–320. https://doi.org/10.1037/0882-7974.17.2.299.; Johnson W, Logie RH, Brockmole JR.Working memory tasks differ in factor structure across age cohorts: Implications for dedifferentiation. Intelligence. 2010;38(5):513–528. https://doi.org/10.1016/j.intell.2010.06.005.; Salthouse TA. Trajectories of normal cognitive aging. Psychol Aging. 2019;34(1):17–24. https://doi.org/10.1037/pag0000288.; Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JC et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52(2):195–204. https://doi.org/10.1111/j.1532-5415.2004.52058.x; Wolf PA. Contributions of the Framingham Heart Study to stroke and dementia epidemiologic research at 60 years. Arch Neurol. 2012;69(5):567–571. https://doi.org/10.1001/archneurol.2011.977.; Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277–281. https://doi.org/10.1212/01.WNL.0000149519.47454.F2.; Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573–591. https://doi.org/10.1161/CIRCRESAHA.116.308426.; Caruso P, Signori R, Moretti R. Small vessel disease to subcortical dementia: a dynamic model, which interfaces aging, cholinergic dysregulation and the neurovascular unit. Vasc Health Risk Manag. 2019;15:259–281. https://doi.org/10.2147/VHRM.S190470.; Rundek T, Tolea M, Ariko T, Fagerli EA, Camargo CJ. Vascular Cognitive Impairment (VCI). Neurotherapeutics. 2022;19(1):68–88. https://doi.org/10.1007/s13311-021-01170-y.; Zlokovic BV, Gottesman RF, Bernstein KE, Seshadri S, McKee A, Snyder H et al. Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement. 2020;16(12):1714–1733. https://doi.org/10.1002/alz.12157.; Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844–866. https://doi.org/10.1016/j.neuron.2013.10.008.; Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–2204. https://doi.org/10.1212/01.wnl.0000271090.28148.24.; Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011;14(6):724–738. https://doi.org/10.1016/j.cmet.2011.08.016.; Toth P, Tarantini S, Csiszar A, Ungvari Z. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. Am J Physiol Heart Circ Physiol. 2017;312(1):H1–H20. https://doi.org/10.1152/ajpheart.00581.2016.; Duncombe J, Kitamura A, Hase Y, Ihara M, Kalaria RN, Horsburgh K. Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementia. Clin Sci (Lond). 2017;131(19):2451–2468. https://doi.org/10.1042/CS20160727.; Park JH, Hong JH, Lee SW, Ji HD, Jung JA, Yoon KW et al. The effect of chronic cerebral hypoperfusion on the pathology of Alzheimer’s disease: A positron emission tomography study in rats. Sci Rep. 2019;9(1):14102. https://doi.org/10.1038/s41598-019-50681-4.; Duering M, Biessels GJ, Brodtmann A, Chen C, Cordonnier C, de Leeuw FE et al. Neuroimaging standards for research into small vessel diseaseadvances since 2013. Lancet Neurol. 2023;22(7):602–618. https://doi.org/10.1016/S1474-4422(23)00131-X.; Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–838. https://doi.org/10.1016/S1474-4422(13)70124-8.; LADIS Study Group. 2001–2011: a decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis. 2011;32(6):577–588. https://doi.org/10.1159/000334498.; Lei C, Deng Q, Li H, Zhong L. Association Between Silent Brain Infarcts and Cognitive Function: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2019;28(9):2376–2387. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.036.; Qiu C, Cotch MF, Sigurdsson S, Jonsson PV, Jonsdottir MK, Sveinbjrnsdottir S et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology. 2010;75(24):2221–2228. https://doi.org/10.1212/WNL.0b013e3182020349.; Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet. 1974;304(7874):207–210. https://doi.org/10.1016/s0140-6736(74)91496-2.; Graff-Radford J. Vascular Cognitive Impairment. Continuum (Minneap Minn). 2019;25(1):147–164. https://doi.org/10.1212/CON.0000000000000684.; Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62(4):406–413. https://doi.org/10.1002/ana.21208.; Tatemichi TK, Desmond DW, Prohovnik I. Strategic infarcts in vascular dementia. A clinical and brain imaging experience. Arzneimittelforschung. 1995;45(3A):371–385. Available at: https://pubmed.ncbi.nlm.nih.gov/7763329/.; Biesbroek JM, Kuijf HJ, van der Graaf Y, Vincken KL, Postma A, Mali WP et al. Association between subcortical vascular lesion location and cognition: a voxel-based and tract-based lesion-symptom mapping study. The SMART-MR study. PLoS ONE. 2013;8(4):e60541. https://doi.org/10.1371/journal.pone.0060541.; Benedictus MR, Hochart A, Rossi C, Boulouis G, Hénon H, van der Flier WM, Cordonnier C. Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage. Stroke. 2015;46(10):2773–2778. https://doi.org/10.1161/STROKEAHA.115.010200.; Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain. 2007;130(8):1988–2003. https://doi.org/10.1093/brain/awl387.; Захаров ВВ. Диагностика и лечение сосудистых когнитивных нарушений. Клиницист. 2023;17(3):12–21. https://doi.org/10.17650/1818-8338-2023-17-3-K694.; Molad J, Kliper E, Korczyn AD, Ben Assayag E, Ben Bashat D, ShenharTsarfaty S e al. Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study. J Alzheimers Dis. 2017;56(4):1293–1299. https://doi.org/10.3233/JAD-160939.; Rasquin SM, Verhey FR, van Oostenbrugge RJ, Lousberg R, Lodder J. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry. 2004;75(11):1562–1567. https://doi.org/10.1136/jnnp.2003.024190.; Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666. https://doi.org/10.1136/bmj.c3666.; Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol. 2006;63(2):246–250. https://doi.org/10.1001/archneur.63.2.246.; Wright CB, Festa JR, Paik MC, Schmiedigen A, Brown TR, Yoshita M et al. White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility. Stroke. 2008;39(3):800–805. https://doi.org/10.1161/STROKEAHA.107.484147.; Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16(3):280–285. https://doi.org/10.1159/000071128.; Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e44–e71. https://doi.org/10.1161/STR.0000000000000116.; Chojdak-Łukasiewicz J, Dziadkowiak E, Zimny A, Paradowski B. Cerebral small vessel disease: A review. Adv Clin Exp Med. 2021;30(3):349–356. https://doi.org/10.17219/acem/131216.; Wen W, Sachdev PS, Li JJ, Chen X, Anstey KJ. White matter hyperintensities in the forties: their prevalence and topography in an epidemiological sample aged 44–48. Hum Brain Mapp. 2009;30(4):1155–1167. https://doi.org/10.1002/hbm.20586.; De Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9–14. https://doi.org/10.1136/jnnp.70.1.9.; Zanon Zotin MC, Sveikata L, Viswanathan A, Yilmaz P. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr Opin Neurol. 2021;34(2):246–257. https://doi.org/10.1097/WCO.0000000000000913.; O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98. https://doi.org/10.1016/s1474-4422(03)00305-3.; Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689–701. https://doi.org/10.1016/S1474-4422(10)70104-6.; Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684–696. https://doi.org/10.1016/S1474-4422(19)30079-1.; Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014;83(14):1228–1234. https://doi.org/10.1212/WNL.0000000000000837.; Xu X, Hilal S, Collinson SL, Chong EJ, Ikram MK, Venketasubramanian N, Chen CL. Association of Magnetic Resonance Imaging Markers of Cerebrovascular Disease Burden and Cognition. Stroke. 2015;46(10):2808–2814. https://doi.org/10.1161/STROKEAHA.115.010700.; Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32(12):2735–2740. https://doi.org/10.1161/hs1201.100209.; Sachdev P, Kalaria R, O’Brien J, Skoog I, Alladi S, Black SE et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206–218. https://doi.org/10.1097/WAD.0000000000000034.; Litak J, Mazurek M, Kulesza B, Szmygin P, Litak J, Kamieniak P, Grochowski C. Cerebral Small Vessel Disease. Int J Mol Sci. 2020;21(24):9729. https://doi.org/10.3390/ijms21249729.; Blevins BL, Vinters HV, Love S, Wilcock DM, Grinberg LT, Schneider JA et al. Brain arteriolosclerosis. Acta Neuropathol. 2021;141(1):1–24. https://doi.org/10.1007/s00401-020-02235-6.; Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease – one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30–42. https://doi.org/10.1038/s41582-019-0281-2.; Yuan L, Chen X, Jankovic J, Deng H. CADASIL: A NOTCH3-associated cerebral small vessel disease. J Adv Res. 2024.https://doi.org/10.1016/j.jare.2024.01.001.; Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35(11 Suppl. 1):2616–2619. https://doi.org/10.1161/01.STR.0000143224.36527.44.; Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A et al. Association of HTRA1 mutations and familial ischemic cerebral smallvessel disease. N Engl J Med. 2009;360(17):1729–1739. https://doi.org/10.1056/NEJMoa0801560.; Chabriat H, Bousser MG. Neuropsychiatric manifestations in CADASIL. Dialogues Clin Neurosci. 2007;9(2):199–208. https://doi.org/10.31887/DCNS.2007.9.2/hchabriat.; Tikka S, Baumann M, Siitonen M, Pasanen P, Pöyhönen M, Myllykangas L et al. CADASIL and CARASIL. Brain Pathol. 2014;24(5):525–544. https://doi.org/10.1111/bpa.12181.; Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–2052. https://doi.org/10.1001/archinte.162.18.2046.; Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553–561. https://doi.org/10.1001/jama.2018.21442.; Nasrallah IM, Pajewski NM, Auchus AP, Chelune G, Cheung AK, Cleveland ML et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019;322(6):524–534. https://doi.org/10.1001/jama.2019.10551.; Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser MG, Guillon P et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation. 2005;112(11):1644–1650. https://doi.org/10.1161/CIRCULATIONAHA.104.501163.; Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279. https://doi.org/10.1016/j.jalz.2011.03.008.; Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2011;42(9):2672–2713. https://doi.org/10.1161/STR.0b013e3182299496.; Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glycerylphosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013;10(10):1070–1079. https://doi.org/10.2174/15672050113106660173.; Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol. 2006;16(6):710–715. https://doi.org/10.1016/j.conb.2006.09.002.; Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev. 2001;122(16):2041–2055. https://doi.org/10.1016/s0047-6374(01)00312-8.; Романова ИС, Кожанова ИН, Чак ТА. Холина альфосцерат в лечении неврологических нарушений. Здравоохранение (Минск). 2022;(10):52–59. Режим доступа: https://www.elibrary.ru/ioxwwb.; Ajenikoko MK, Ajagbe AO, Onigbinde OA, Okesina AA, Tijani AA. Review of Alzheimer’s disease drugs and their relationship with neuron-glia interaction. IBRO Neurosci Rep. 2022;14:64–76. https://doi.org/10.1016/j.ibneur.2022.11.005.; Yu JH, Kim LY, Kim JM, Park MJ, Park YS, Park NS, Yang WD. The effect of choline alphoscerate on non spatial memory and neuronal differentiation in a rat model of dual stress. Brain Res. 2022;1786:147900. https://doi.org/10.1016/j.brainres.2022.147900.; Barbagallo Sangiorgi G, Barbagallo M, Giordano M, Meli M, Panzarasa R. α-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci. 1994;717(1):253–269. https://doi.org/10.1111/j.1749-6632.1994.tb12095.x.; Di Perri R, Coppola G, Ambrosio LA, Grasso A, Puca FM, Rizzo M. A multicentre trial to evaluate the efficacy and tolerability of alphaglycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19(4):330–341. https://doi.org/10.1177/030006059101900406.; Румянцева СА, Кравчук АА, Рыжова ДД. Терапия когнитивных расстройств у больных хронической ишемией головного мозга. РМЖ. 2007;(5):379–383. Режим доступа: https://www.rmj.ru/articles/nevrologiya/Terapiya_kognitivnyh_rasstroystv_u_bolynyh_hronicheskoy_ishemiey_golovnogo_mozga/.; Менделевич ЕГ, Сурженко ИЛ, Дунин ДН, Богданов ЭИ. Церетон в лечении когнитивных нарушений у больных дисциркуляторной и посттравматической энцефалопатией. РМЖ. 2009;(5):382–387. Режим доступа: https://www.rmj.ru/articles/nevrologiya/Cereton_v_lechenii_kognitivnyh_narusheniy__u_bolynyh_discirkulyatornoy_i_posttravmaticheskoy_encefalopatiey/.; Соловьева АВ, Чичановская ЛВ, Бахарева ОН, Брянцева МВ. Изучение эффективности препарата Церетон в лечении больных пожилого возраста, страдающих хронической ишемией головного мозга. РМЖ. 2009;(23):1522–1525. Режим доступа: https://www.rmj.ru/articles/nevrologiya/Izuchenie_effektivnosti_preparata_Cereton__v_lechenii_bolynyh_poghilogo_vozrasta__stradayuschih_hronicheskoy_ishemiey_golovnogo_mozga/.; Батышева ТТ, Нестерова ОС, Отческая ОВ, Хозова АА, Зайцев КС, Камчатнов ПР, Бойко АН. Применение Церетона у больных с умеренными когнитивными расстройствами сосудистого генеза. Трудный пациент. 2009;7(4-5):10–12. Режим доступа: https://www.elibrary.ru/ogaixn.; Traini E, Carotenuto A, Fasanaro AM, Amenta F. Volume Analysis of Brain Cognitive Areas in Alzheimer’s Disease: Interim 3-Year Results from the ASCOMALVA Trial. J Alzheimers Dis. 2020;76(1):317–329. https://doi.org/10.3233/jad-190623.; Levin OS, Batukaeva LA, Anikina MA, Yunishchenko NA. Efficacy and safety of choline alphoscerate (cereton) in patients with Parkinson’s disease with cognitive impairments. Neurosci Behav Physiol. 2011;4:47–51. https://doi.org/10.1007/s11055-010-9377-2.; Salvadori E, Poggesi A, Donnini I, Rinnoci V, Chiti G, Squitieri M et al. Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial. Drugs Aging. 2021;38(6):481–491. https://doi.org/10.1007/s40266-021-00852-8; https://www.med-sovet.pro/jour/article/view/8466

الاتاحة: https://www.med-sovet.pro/jour/article/view/8466
https://doi.org/10.21518/ms2024-311

المؤلفون: T. N. Zvereva, E. I. Zhidkova, K. Yu. Medvedeva, E. E. Pomeshkina, O. E. Filatova, L. A. Chereneva, A. S. Agienko, S. A. Pomeshkina, Т. Н. Зверева, Е. И. Жидкова, К. Ю. Медведева, Е. Е. Помешкина, О. Е. Филатова, Л. А. Черенева, А. С. Агиенко, С. А. Помешкина

المساهمون: Исследование выполнено в рамках Комплексной научно-технической программы полного инновационного цикла «Разработка и внедрение комплекса технологий в области разведки и добычи твердых полезных ископаемых, обеспечения промышленной безопасности, биоремедиации, создания новых продуктов глубокой переработки из угольного сырья при последовательном снижении экологической нагрузки на окружающую среду и рисков для жизни населения» (утв. Распоряжением Правительства РФ от 11 мая 2022 г. № 1144-р).

المصدر: The Siberian Journal of Clinical and Experimental Medicine; Том 37, № 4 (2022); 188-196 ; Сибирский журнал клинической и экспериментальной медицины; Том 37, № 4 (2022); 188-196 ; 2713-265X ; 2713-2927

مصطلحات موضوعية: обучающая информация, cardiovascular disease, healthy lifestyle, cardiovascular risk factors, patient medical literacy, educational information, сердечно-сосудистые заболевания, здоровый образ жизни, сердечно-сосудистые факторы риска, медицинская грамотность пациентов

وصف الملف: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/1637/774; Visseren F.L.J., Francois M., Smulders Y.M., Carballo D.M., Koskinas K.C., Bäck M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021;42(34):3227–3337. DOI:10.1093/eurheartj/ehab484.; Ларина В.Н., Мкртычев Д.С., Кузнецова В.А., Тяжельников А.А. Возможные подходы к первичной профилактике сердечно-сосудистых заболеваний. Рациональная Фармакотерапия в Кардиологии. 2020;16(5):831–841. DOI:10.20996/1819-6446-2020-10-12.; Шальнова С.А., Баланова Ю.А., Деев А.Д., Концевая А.В., Имаева А.Э., Капустина А.В. и др. Интегральная оценка приверженности здоровому образу жизни как способ мониторинга эффективности профилактических мер. Профилактическая медицина. 2018;21(4):65–72. DOI:10.17116/profmed201821465.; Чулков В.С., Гаврилова Е.С., Чулков Вл.С., Панкова Е.Д., Ленец Е.А., Ткаченко П.Е. Первичная профилактика сердечно-сосудистых заболеваний: акцент на коррекцию поведенческих факторов риска. Российский кардиологический журнал. 2021;26(3S):4278. DOI:10.15829/1560-4071-2021-4278.; Калинина А.М., Кушунина Д.В., Горный Б.Э., Антонов К.А., Бетяева О.В., Соколов Г.Е. Потенциал профилактики сердечно-сосудистых заболеваний по результатам диспансеризации взрослого населения. Кардиоваскулярная терапия и профилактика. 2019;18(4):69– 76. DOI:10.15829/1728-8800-2019-4-69-76; Указ Президента Российской Федерации от 07.05.2018 г. № 204 «О национальных целях и стратегических задачах развития Российской Федерации на период до 2024 года». URL: http://www.kremlin.ru/acts/bank/43027; Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7– 122. DOI:10.15829/1560-4071-2018-6-7-122.; Драпкина О.М., Самородская И.В., Старинская М.А., Бойцов С.А. Сравнение российских регионов по уровню стандартизованных коэффициентов смертности от всех причин и болезней системы кровообращения в 2006–2016 гг. Профилактическая медицина. 2018;21(4):4–12. DOI:10.17116/profmed20182144.; Барбараш О.Л., Артамонова Г.В., Индукаева Е.В., Максимов С.А. Международное эпидемиологическое исследование неинфекционных заболеваний в России: протокол исследования. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(4):128–135. DOI:10.17802/2306-1278-2018-7-4-128-135.; Погосова Н.В., Оганов Р.Г., Бойцов С.А., Аушева А.К., Соколова О.Ю., Курсаков А.А. и др. Эффективность первичной профилактики заболеваний, обусловленных атеросклерозом, у пациентов с высоким сердечно-сосудистым риском в России и других странах Европы (часть 1). Кардиология. 2017;57(1S):333–344. DOI:10.18087/cardio.2411.; Погосова Н.В., Оганов Р.Г., Бойцов С.А., Аушева А.К., Соколова О.Ю., Курсаков А.А. и др. Анализ ключевых показателей вторичной профилактики у пациентов с ишемической болезнью сердца в России и Европе по результатам российской части международного многоцентрового исследования EUROASPIRE V. Кардиоваскулярная терапия и профилактика. 2020;19(6):2739. DOI:10.15829/1728-8800-2020-2739.; Мухамедгалиева А., Сабитова Г., Касенова Б., Оркашбаева Б. Повышение медицинской грамотности пациентов путем их обучения во взрослом стационарном кардиологическом отделении. Евразийское Научное Объединение. 2021;6–3(76):189–197.; https://www.sibjcem.ru/jour/article/view/1637

الاتاحة: https://www.sibjcem.ru/jour/article/view/1637
https://doi.org/10.29001/2073-8552-2022-37-4-188-196

المؤلفون: Rotaru, L.A., Ротару, Л.

المصدر: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 67 (3) 74-77

مصطلحات موضوعية: boala Parkinson, migrena, factori de risc vasculari, performanță cognitive, performanță motorie, Parkinson’s disease, migraine, vascular risk factors, cognitive performance, motor performance, болезнь Паркинсона, мигрень, сосудистые факторы риска, когнитивные способности, двигательная активность

وصف الملف: application/pdf

Relation: info:eu-repo/grantAgreement/EC/FP7/17191/EU/Tulburări cognitive majore (demență) la pacienții cu patologie neurodegenerativă și vasculară/20.80009.8007.39; https://ibn.idsi.md/vizualizare_articol/114478; urn:issn:18570011

الاتاحة: https://ibn.idsi.md/vizualizare_articol/114478

المؤلفون: Rotaru, L.A., Ротару, Л.

المصدر: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 67 (3) 39-45

مصطلحات موضوعية: boala Parkinson, boli cardiovasculare, factori de risc vascular, Parkinson’s disease, cardiovascular disease, vascular risk factors, болезнь Паркинсона, сердечно-сосудистые заболевания, сосудистые факторы риска

وصف الملف: application/pdf

Relation: info:eu-repo/grantAgreement/EC/FP7/17191/EU/Tulburări cognitive majore (demență) la pacienții cu patologie neurodegenerativă și vasculară/20.80009.8007.39; https://ibn.idsi.md/vizualizare_articol/114474; urn:issn:18570011

الاتاحة: https://ibn.idsi.md/vizualizare_articol/114474

المؤلفون: N. Pizova V., N. Pizov A., O. Skachkova A., M. Sokolov A., I. Izmaylov A., R. Taramakin B., Н. Пизова В., Н. Пизов А., О. Скачкова А., М. Соколов А., И. Измайлов А., Р. Тарамакин Б.

المصدر: Meditsinskiy sovet = Medical Council; № 8 (2020); 18-25 ; Медицинский Совет; № 8 (2020); 18-25 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: coronavirus disease, vascular risk factors, neurological complications, ischemic stroke, ethylmethylhydroxypyridine succinate, коронавирусная болезнь, сосудистые факторы риска, неврологические осложнения, ишемический инсульт, этилметилгидроксипиридина сукцинат

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5676/5176; Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O. et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268–2270. doi:10.1056/NEJMc2008597.; Chen T., Wu D., Chen H., Yan W., Yang D., Chen G. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar 31;368:m1295]. BMJ. 2020;368:m1091. doi:10.1136/bmj.m1091.; Divani А.А., Andalib S., Di Napoli V., Lattanzi S., Hussain M.S., Biller J. et al. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights. J Stroke Cerebrovasc Dis. 2020;29(8):104941. doi:10.1016/j.jstrokecerebrovasdis.2020.104941.; Zhao J., Rudd A., Liu R. Challenges and Potential Solutions of Stroke Care During the Coronavirus Disease 2019 (COVID-19) Outbreak. Stroke. 2020;51(5):1356–1357. doi:10.1161/STROKEAHA.120.029701.; Sharifi-Razavi A., Karimi N., Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental?. New Microbes New Infect. 2020;35:100669. doi:10.1016/j.nmni.2020.100669.; Qin C., Zhou L., Hu Z., Yang S., Zhang S., Chen M. et al. Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, China. Stroke. 2020;51(7):2219–2223. doi:10.1161/STROKEAHA.120.030365.; Yaghi S., Ishida K., Torres J., Mac Grory B., Raz E., Humbert K. et al. SARS2- CoV-2 and Stroke in a New York Healthcare System. Stroke. 2020;51(7):2002–2011. doi:10.1161/STROKEAHA.120.030335.; Mao L., Jin H., Wang M., Chen S., He Q., Chang J. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):1–9. doi:10.1001/jamaneurol.2020.1127.; Li Y., Wang M., Zhou Y., Chang J., Xian Y., Mao L. et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN Electronic Journal. 2020. doi:10.2139/ssrn.3550025.; Weston S., Frieman M.B. COVID-19: Knowns, Unknowns, and Questions. mSphere. 2020;5(2):e00203–20. doi:10.1128/mSphere.00203-20.; Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi:10.1016/j.ijid.2020.03.017.; Emami A., Javanmardi F., Pirbonyeh N., Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020;8(1):e35. Available at: https://pubmed.ncbi.nlm.nih.gov/32232218.; Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013.; Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.; Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020. doi:10.1001/jama.2020.4683.; Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI137244.; Conti P., Ronconi G., Caraffa A., Gallenga C.E., Ross R., Frydas I. et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1. doi:10.23812/CONTI-E.; Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. doi:10.1002/path.1570.; Arabi Y.M., Balkhy H.H., Hayden F.G., Bouchama A., Luke T., Baillie J.K. et al. Middle East Respiratory Syndrome. N Engl J Med. 2017;376(6):584–594. doi: 0.1056/NEJMsr1408795.; Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020;20(5):277. doi:10.1038/s41577-020-0305-6.; Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi:10.1111/jth.14768.; Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.0994.; Lippi G., Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190–191. doi:10.1016/j.cca.2020.03.004.; Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W. et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38. doi:10.1056/NEJMc2007575.; Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi:10.1016/S0140-6736(20)30937-5.; Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168–175. doi:10.1161/01.atv.0000051384.43104.fc.; Flammer A.J., Anderson T., Celermajer D.S., Creager M.A., Deanfield J., Ganz P. et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126(6):753–767. doi:10.1161/CIRCULATIONAHA.112.093245.; Ding Y., Wang H., Shen H., Li Z., Geng J., Han H. et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–289. doi:10.1002/path.1440.; Wang C., Pan R., Wan X., Tan Y., Xu L., Ho C.S., Ho R.C. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. doi:10.3390/ijerph17051729.; Khosravani H., Rajendram P., Notario L., Chapman M.G., Menon B.K. Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic. Stroke. 2020;51(6):1891–1895. doi:10.1161/STROKEAHA.120.029838.; Montaner J., Barragán-Prieto A., Pérez-Sánchez S., Escudero-Martínez I., Moniche F., Sánchez-Miura J.A. et al. Break in the Stroke Chain of Survival Due to COVID-19. Stroke. 2020. doi:10.1161/STROKEAHA.120.030106.; Klijn C.J., Paciaroni M., Berge E., Korompoki E., Kõrv J., Lal A. et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019;4(3):198–223. doi:10.1177/2396987319841187.; Palnum K.H., Mehnert F., Andersen G., Ingeman A., Krog B.R., Bartels P.D., Johnsen S.P. Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: a nationwide follow-up study. Stroke. 2012;43(3):802–807. doi:10.1161/STROKEAHA.111.635342.; Asberg S., Henriksson K.M., Farahmand B., Asplund K., Norrving B., Appelros P. et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register. Stroke. 2010;41(7):1338–1342. doi:10.1161/STROKEAHA.110.580209.; Bernhardt J., Dewey H., Thrift A., Collier J., Donnan G. A very early rehabilitation trial for stroke (AVERT): phase II safety and feasibility. Stroke. 2008;39(2):390–396. doi:10.1161/STROKEAHA.107.492363.; Veerbeek J.M., van Wegen E., van Peppen R., van der Wees P.J., Hendriks E., Rietberg M., Kwakkel G. What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. PLoS One. 2014;9(2):e87987. doi:10.1371/journal.pone.0087987.; Танашян М.М., Домашенко М.А., Максимова М.Ю. Современная нейропротекция в комплексном лечении пациентов в остром и раннем восстановительном периоде ишемического инсульта. Нервные болезни. 2017;(3):36–41. Режим доступа: https://www.neurology.ru/sites/default/files/assets/documents/2017/11/nb-3-2017-36.pdf?download=1.; Прокопенко С.В., Шанина Е.Г., Петрова М.М., Можейко Е.Ю. Нейрорепарация: современные взгляды на проблему. Фарматека. 2014;(13):20–24. https://pharmateca.ru/ru/archive/article/30171.; Романова Г.А., Шакова Ф.М., Барсков И.В., Стельмашук Е.В., Петров Т.В., Соколов М.А. и др. Влияние целлекса на функциональные и морфологические изменения при экспериментальной фокальной ишемии префронтальной коры головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуск. 2010;110(9):52–56. Режим доступа: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova-2/2010/9/031997-72982010910.; Хасанова Д.Р., Данилова Т.В., Дёмин Т.В., Кнни К.С., Гайфутдинова Л.В. Влияние препарата Целлекс на восстановление двигательных и речевых функций в ранней нейрореабилитации пациентов, перенесших ишемический инсульт. Медицинский совет. 2018;(9):14–19. doi:10.21518/2079-701X-2018-9-14-19.; Пизова Н.В., Соколов М.А., Измайлов И.А. Целлекс в лечении больных с острым нарушением мозгового кровообращения: результаты российскоо многоцентрового сравнительного открытого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;(5):22–26. Режим доступа: https://www.mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2014/5/031997-7298201454.; Бельская Г.Н., Пизова Н.В., Соколов М.А., Измайлов И.А. Влияние нейропротективной терапии на течение церебрального инсульта. Медицинский совет. 2016;(11):14–19. doi:10.21518/2079-701X-2016-11-26-31.; Бельская Г.Н., Чуприна С.Е., Воробьев А.А., Горожа Е.Н., Буторакина Т.Л., Соколов М.А., Измайлов И.А. Когнитивные нарушения при инсульте: возможности медикаментозной коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(5):33–37. doi:10.17116/jnevro20161165133-37.; Котов С.В., Белова Ю.А., Щербакова М.М., Червинская А.Д., Исакова Е.В., Волченкова Е.В. Восстановление речевых функций у больных с афазией в раннем реабилитационном периоде ишемического инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(2):38–41. doi:10.17116/jnevro20171172138-41.; Коваленко А.В., Сафронова М.Н. Влияние целлекса на восстановление когнитивных и речевых нарушений в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(1):40–44. doi:10.17116/jnevro20151151140-44.; Бельская Г.Н., Крылова Л.Г., Соколов М.А., Измайлов И.А. Возможности коррекции речевых расстройств в остром периоде ишемического инсульта с помощью нейропротективной терапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(9):60–63. doi:10.17116/jnevro20151159260-63.; Ковальчук В.В., Гусев А.О., Миннуллин Т.И., Нестерин К.В. Реабилитация пациентов после инсульта. Критерии эффективности и факторы успеха: роль физической, нейропсихологической и медикаментозной терапии. Эффективная фармакотерапия. Неврология и психиатрия. Спецвыпуск «Мысли, знания и опыт ведущих ученых-неврологов Санкт-Петербурга». 2017;(19):62–73. Режим доступа: https://umedp.ru/articles/reabilitatsiya_patsientov_posle_insulta_kriterii_effektivnosti_i_faktory_uspekha_rol_fizicheskoy_ney.html.; https://www.med-sovet.pro/jour/article/view/5676

الاتاحة: https://www.med-sovet.pro/jour/article/view/5676
https://doi.org/10.21518/2079-701X-2020-8-18-25

المؤلفون: Rotaru, Lilia

المصدر: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 67 No. 3 (2020): Medical Sciences; 39-45 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 67 Nr. 3 (2020): Ştiinţe medicale; 39-45 ; Вестник Академии Наук Молдовы. Медицина; Том 67 № 3 (2020): Медицина; 39-45 ; 1857-0011

مصطلحات موضوعية: болезнь Паркинсона, сердечно-сосудистые заболевания, сосудистые факторы риска, Parkinson’s disease, cardiovascular disease, vascular risk factors, boala Parkinson, boli cardiovasculare, factori de risc vascular

وصف الملف: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3245/3245; https://bulmed.md/bulmed/article/view/3245

الاتاحة: https://bulmed.md/bulmed/article/view/3245

المؤلفون: Romanciuc, L.V., Романчук, Л.В.

المصدر: Buletin de Perinatologie 84 (3) 19-23

مصطلحات موضوعية: obezitate, factori de risc cardiovascular, copii, ожирение, сердечно-сосудистые факторы риска, дети

وصف الملف: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/90355; urn:issn:18105289

الاتاحة: https://ibn.idsi.md/vizualizare_articol/90355

المؤلفون: Vataman, E.B., Anestiadi, V.V., Calenici, E., Grossu, A.G.

المصدر: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 61 (1) 161-165

مصطلحات موضوعية: factori de risc cardiovascular, afectare aterosclerotică, artere coronare și carotide, cardiovascular risk factors, atherosclerotic impairment, coronary and carotid arteries, сердечно-сосудистые факторы риска, атеросклеротические поражения, коронарные и сонные артерии.

وصف الملف: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/75822; urn:issn:18570011

الاتاحة: https://ibn.idsi.md/vizualizare_articol/75822

المؤلفون: Vataman, Eleonora, Anestiadi, Vasile, Calenici, Eugeniu, Grossu, Ala

المصدر: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 61 No. 1 (2019): Medical Sciences; 161-165 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 61 Nr. 1 (2019): Ştiinţe medicale; 161-165 ; Вестник Академии Наук Молдовы. Медицина; Том 61 № 1 (2019): Медицина; 161-165 ; 1857-0011

مصطلحات موضوعية: сердечно-сосудистые факторы риска, атеросклеротические поражения, коронарные и сонные артерии., cardiovascular risk factors, atherosclerotic impairment, coronary and carotid arteries, factori de risc cardiovascular, afectare aterosclerotică, artere coronare și carotide

وصف الملف: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3007/3007; https://bulmed.md/bulmed/article/view/3007

الاتاحة: https://bulmed.md/bulmed/article/view/3007

المؤلفون: D. A. Anichkov, N. A. Shostak, A. D. Zhuravleva

المصدر: Рациональная фармакотерапия в кардиологии, Vol 1, Iss 1, Pp 37-42 (2015)

مصطلحات موضوعية: менопауза, сердечно-сосудистые факторы риска, модификация образа жизни, фармакологическое лечение, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/341; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

URL الوصول: https://doaj.org/article/464d263be84041c8b1f19f99cbf0c699

المؤلفون: A. V. Arshinov, N. Yu. Levshin, I. G. Maslova, А. В. Аршинов, Н. Ю. Левшин, И. Г. Маслова

المصدر: Rheumatology Science and Practice; Vol 55, No 3 (2017); 304-310 ; Научно-практическая ревматология; Vol 55, No 3 (2017); 304-310 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20173

مصطلحات موضوعية: лечение сердечно-сосудистых событий, atherosclerosis, nontraditional cardiovascular risk factors, treatment of cardiovascular events, атеросклероз, нетрадиционные сердечно-сосудистые факторы риска

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2383/1583; Насонов ЕЛ. Антифосфолипидный синдром. Москва: Литтерра; 2004. 440 с. [Nasonov EL. Antifosfolipidnyi sindrom [Antiphospholipid syndrome]. Moscow: Litterra; 2004. 440 p.].; EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205. doi:10.1136/ard.2007.070367; Liu Z, Davidson A. Taming lupus – a new understanding of pathogenesis is leading to clinical advances. Nature Medicine. 2012;18(6):871-82. doi:10.1038/nm.2752; D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587-96. doi:10.1016/S0140- 6736(07)60279-7; Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med. 1985;55(216):87-98.; Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221-5. doi:10.1016/0002-9343(76)90431-9; Bjö rnadal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964- 95. J Rheumatol. 2004;31(4):713-9.; Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus. 2007;16(5):309-17. doi:10.1177/0961203307077987; Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, et al. Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis. 2013;2013:Article ID 794383, 20 p. doi:10.1155/2013/794383; McMahon M, Skaggs B. Pathogenesis and treatment of atherosclerosis in lupus. Rheum Dis Clin North Am. 2014;40(3):475-95.; Van Leuven SI, van Wijk DF, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis. 2010;211(1):231-6. doi:10.1016/j.atherosclerosis.2010.01.043; Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004;114(5-6):593-5. doi:10.1016/j.thromres.2004.07.012; Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176(8):708-19. doi:10.1093/aje/kws130; Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331-7. doi:10.1002/1529- 0131(200110)44:103.0.CO;2-I; Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:345-51. doi:10.1097/00002281-200109000-00002; Bruce IN. 'Not only. but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005;44(12):1492-502. doi:10.1093/rheumatology/kei142; Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates ofmyocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Amer J Epidemiol. 1997;145(5):408-15. doi:10.1093/oxfordjournals.aje.a009122; Kiani AN, Magder LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int. 2012;32(9):2701-5. doi:10.1007/s00296-011-2048-y; Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Amer J Med. 2006;119(8):700-6. doi:10.1016/j.amjmed.2005.11.034; Ильина АЕ, Клюквина НГ, Александрова ЕН и др. Атеросклеротическое поражение сосудов при системной красной волчанке и антифосфолипидном синдроме у мужчин. Клиническая медицина. 2006;(4):23-8 [Il'ina AE, Klyukvina NG, Aleksandrova EN, et al. Atherosclerotic vascular lesions in systemic lupus erythematosus and antiphospholipid syndrome in men. Klinicheskaya Meditsina. 2006;(4):23-8 (In Russ.)].; McMahon M, Grossman J, Chen W, et al. Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus. Lupus. 2006;15:59-69. doi:10.1177/0961203306071668; Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev. 2013;19(1):15-9.; Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus. 2011;20(1):5-13. doi:10.1177/0961203310382429; Ames PR, Margarita A, Sokoll KB, et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64(2):315-7. doi:10.1136/ard.2004.023952; Ames PR, Margarita A, Alves JD. Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009;37(1):29-35. doi:10.1007/s12016-008-8099-5; Gresele P, Migliacci R, Vedovati MC, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009;123(3):444-51. doi:10.1016/j.thromres.2008.05.015; Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus. 2010;19(4):419-23. doi:10.1177/0961203309360541; O'Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):845-54. doi:10.1002/art.27286; Mandal K, Foteinos G, Jahangiri M, et al. Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus. 2005;14(9):742-6. doi:10.1191/0961203305lu2212oa; Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep. 2013;15(9):360. doi:10.1007/s11926-013-0360-0; Motoki Y, Nojima J, Yanagihara M, et al. Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells. Thromb Res. 2012;130(4):667-73. doi:10.1016/j.thromres.2011.11.048; Loeffen R, Spronk HM, ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost. 2012;10(7):1207-16. doi:10.1111/j.1538- 7836.2012.04782.x; Boles J, Mackman N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus. 2010;19(4):370-8. doi:10.1177/0961203309360810; Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation. 2009;120:2012-24. doi:10.1161/CIRCULATIONAHA.108.771170; Tsokos GC. Mechanisms of disease systemic lupus erythematosus. N Engl J Med. 2011;365:2110-21. doi:10.1056/NEJMra1100359; Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004;103:3677-83. doi:10.1182/blood-2003-09-3198; Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis. 2015;74(7):1450-8. doi:10.1136/annrheumdis-2013-204351; Thacker SG, Duquaine D, Park J, et al. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus. 2010;19(3):288-99. doi:10.1177/0961203309353773; Thacker SG, Zhao W, Smith CK, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum. 2012;64(9):2975-85. doi:10.1002/art.34504; Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053-63. doi:10.1084/jem.20101664; Knight JS, Kaplan MJ. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol. 2013;25(5):597-605. doi:10.1097/BOR.0b013e328363eba3; Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5. doi:10.1126/science.1092385; Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol. 2012;198(5):773-83. doi:10.1083/jcb.201203170; Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107(21):9813-8. doi:10.1073/pnas.0909927107; Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012;188(7):3522-31. doi:10.4049/jimmunol.1102404; Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20. doi:10.1126/scitranslmed.3001201; Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19.; Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187(1):538-52. doi:10.4049/jimmunol.1100450; Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-94. doi:10.1056/NEJMra071014; Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol. 2012;34(1):5-30. doi:10.1007/s00281-011-0286-4; Tam LS, Fan B, Li EK, et al. Patients with systemic lupus erythematosus show increased platelet activation and endothelial dysfunction induced by acute hyperhomocysteinemia. J Rheumatol. 2003;30(7):1479-84.; Duffau P, Seneschal J, Nicco C, et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med. 2010;2(47):47ra63. doi:10.1126/scitranslmed.3001001; Kaiser R, Li Y, Chang M, et al. Genetic risk factors for thrombosis in systemic lupus erythematosus. J Rheumatol. 2012;39(8):1603- 10. doi:10.3899/jrheum.111451; Chang YH, Lin IL, Tsay GJ, et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem. 2008;41(12):955-9. doi:10.1016/j.clinbiochem.2008.04.012; Bahrehmand F, Vaisi-Raygani A, Kiani A, et al. Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus. 2012;21(6):616-24. doi:10.1177/0961203312436857; McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2428-37. doi:10.1002/art.24677; Zampieri S, Iaccarino L, Ghirardello A, et al. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci. 2005;1051:351-61. doi:10.1196/annals.1361.077; Kawai VK, Solus JF, Oeser A, et al. Novel cardiovascular risk prediction models in patients with systemic lupus erythematosus. Lupus. 2011;20(14):1526-34. doi:10.1177/0961203311420317; Symmons DPM, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7(7):399-408. doi:10.1038/nrrheum.2011.75; Urowitz MB, Gladman D, Ibanez D, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62:881-7. doi:10.1002/acr.20122; Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthr Rheum. 2013;43(1):77-95. doi:10.1016/j.semarthrit.2012.12.002; Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol. 2009;25(10):567-79. doi:10.1016/S0828-282X(09)70715-9; Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266-73. doi:10.1016/j.jacc.2010.01.020; Pons-Estel GJ, Gonzalez LA, Zhang J, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford). 2009;487:817-22. doi:10.1093/rheumatology/kep102; Gustafsson J, Simard JF, Gunnarsson I, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14(2):46. doi:10.1186/ar3759; Nikpour M, Harvey PJ, Ibanez D, et al. High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. Arthritis Rheum. 2012;64(9):3052-3. doi:10.1002/art.34541; Wu GC, Liu HR, Leng RX, et al. Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmun Rev. 2016;15(1):22-37. doi:10.1016/j.autrev.2015.10.002; Tselios K, Sheane BJ, Gladman DD, Urowitz MB. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: A systematic review. J Rheumatol. 2016;43(1):54-65. doi:10.3899/jrheum.150460; Petri M, Magder L. SLE cardiovascular risk equation. Lupus. 2013;22(1):3-5.; Jastrzebska M, Czok ME, Guzik P. Autoimmune diseases, their pharmacological treatment and the cardiovascular system. Cardiol J. 2013;20(6):569-76. doi:10.5603/CJ.2013.0156; Fardet L. Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion. Br J Dermatol. 2007;157:142-8. doi:10.1111/j.1365-2133.2007.07950.x; Nakajima A, Doki K, Homma M, et al. Investigation of glucocorticoidinduced side effects in patients with autoimmune diseases. Yakugaku Zasshi. 2009;129:445-50. doi:10.1248/yakushi.129.445; Linos E, Fiorentino D, Lingala B. Atherosclerotic cardiovascular disease and ermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther. 2013;15:1-5. doi:10.1186/ar4135; Tisseverasinghe A, Bernatsky S, Pineau C. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol. 2009;36:1-4. doi:10.3899/jrheum.090061; Selzer F, Sutton-Tyrrell K, Fitzgerald S, et al. Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001;37(4):1075-82. doi:10.1161/01.HYP.37.4.1075; Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399-406. doi:10.1056/NEJMoa035471; Rahman P, Gladman DD, Urowitz MB, et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol. 1999;26(2):325-30.; Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863-8. doi:10.1002/art.27289; Law G, Magder LS, Fang H, et al. Hydroxychloroquine Reduces Thrombosis (BOTH ARTERIAL AND VENOUS) in Systemic LUPUS Erythematosus, Particularly in Antiphospholipid Positive Patients. American College of Rheumatology 76th Annual Meeting; November 9-14, 2012. Washington, D.C.; 2012.; Costedoat-Chalumeau N, Hulot JS. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology. 2007;46:808-10. doi:10.1093/rheumatology/kel402; Iudici M, Fasano S, Gabriele Falcone L, et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016;55(9):1623-30. doi:10.1093/rheumatology/kew231; Van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, et al. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(–/–) mice. Ann Rheum Dis. 2012;71(3):408-14. doi:10.1136/annrheumdis-2011-200071; Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482-9. doi:10.1093/eurheartj/ehu403; Aprahamian T, Bonegio RG, Richez C, et al. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol. 2009;182(1):340-6. doi:10.4049/jimmunol.182.1.340; Zhao W, Thacker SG, Hodgin JB, et al. The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol. 2009;183(4):2729-40. doi:10.4049/jimmunol.0804341; Zuarez-Rojas JG, Medina-Urrutia AX, Jorge-Galarza E, et al. Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. Lupus. 2012;21(1):27-35. doi:10.1177/0961203311422096; Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res. 2013;56(2-3):348-57. doi:10.1007/s12026-013- 8409-8; Willis R, Seif AM, McGwin G Jr, et al. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multiethnic US cohort. Clin Exp Rheumatol. 2014;32(2):162-7.; Lawman S, Mauri C, Jury EC, et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol. 2004;173(12):7641-6. doi:10.4049/jimmunol.173.12.7641; Aprahamian T, Bonegio R, Rizzo J, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol. 2006;177(5):3028- 34. doi:10.4049/jimmunol.177.5.3028; Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011;70:760-5. doi:10.1136/ard.2010.136762; Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285-96. doi:10.1002/art.30645; https://rsp.mediar-press.net/rsp/article/view/2383

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2383
https://doi.org/10.14412/1995-4484-2017-304-310

مصطلحات موضوعية: cardiovascular risk factors, пожилые, прогнозирование, сердечно-сосудистые факторы риска, сенсорные дефициты, prognosis, sensory deficits, elderly

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::82b74f1ed1a7038ff43c7ead363a321a

المصدر: ScienceRise: Medical Science; № 5(44) (2021); 16-21
ScienceRise: Medical Science; No. 5(44) (2021); 16-21

مصطلحات موضوعية: ischaemic stroke, ишемический инсульт, Е-селектин, E-selectin, ішемічний інсульт, сосудистые факторы риска, атеросклеротический стеноз сонной артерии, судинні фактори ризику, атеросклеротичний каротидний стеноз, ліпопротеїн-асоційована фосфоліпаза А2, vascular risk factors, atherosclerotic carotid stenosis, lipoprotein-associated phospholipase A2, липопротеин-ассоциированная фосфолипаза А2

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=scientific_p::5e19d1aa9fdce9bedcf05d79f506d49a
http://journals.uran.ua/sr_med/article/view/241147

المؤلفون: D. Anichkov A., N. Shostak A., A. Zhuravleva D., Д. Аничков А., Н. Шостак А., А. Журавлева Д.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 1, No 1 (2005); 37-42 ; Рациональная Фармакотерапия в Кардиологии; Vol 1, No 1 (2005); 37-42 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2005-1-1

مصطلحات موضوعية: Menopause, cardiovascular risk factors, lifestyle modification, pharmacological treatment, менопауза, сердечно-сосудистые факторы риска, модификация образа жизни, фармакологическое лечение

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/341/360; Gordon T, Kannel WB, Hjortland MC. Menopause and coronary heart disease: the Framingham study. Ann Intern Med 1978;89:157–61.; Witteman JC, Grobbee DE, Kok FJ, et al. Increased risk of atherosclerosis in women after the menopause. BMJ 1989;298:642–4.; Edmunds E, Lip GY. Cardiovascular risk in women: the cardiologist's perspective. QJM. 2000;93(3):135-45.; Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353:571–80.; Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19(4):397–428.; Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207–18.; Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404–11.; Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:341–55.; Faria AN, Ribeiro Filho FF, Gouveia Ferreira SR, Zanella MT. Impact of visceral fat on blood pressure and insulin Sensitivity in hypertensive obese women. Obes Res 2002;10:1203–6.; Brochu M, Starling RD, Tchernof A, et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab 2000;85:2378–84.; Rendell M, Hulthen UL, Tornquist C, et al. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001;86:744–9.; Hernandez-Ono A, Monter-Carreola G, Zamora-Gonzalez J, et al. Association of visceral fat with coronary risk factors in populationbased sample of postmenopausal women. Int J obes Relat Metab Disord 2001;26:33–9.; Van Pelt RE, Evans EM, Schechtman KB, et al. Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Obes Relat Metab Disord 2001;25:1183–8.; Lovergrove JA, Silva KDRR, Wright JW, Williams CM. Adiposity, insulin and lipid metabolism in post-menopausal women. Int J Obes Relat Metab Disord 2002;26:475–86.; Kuh D, Langenberg C, Hardy R, et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 2005;112(4):476–85.; LaRosa JC. Evidence-based management of dyslipidemias in women. Curr Atheroscler Rep 2003;5:379–85.; Effects of estrogen or estrogen/progestin regimens on heart diseases risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208.; Randomized comparison of oestrogen versus oestrogen plus progesterone hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework. BMJ 1996;312:473–8.; Shakir YA, Samsioe G, Nyberg P, et al. Cardiovascular risk factors in middle-aged women and the association with use of hormone therapy: results from a population-based study of Swedish women. The Women's Health in the Lund Area (WHILA) Study. Climacteric 2004;7(3):274–83.; Nilsson PM, Lind L, Pollare T., et al. Differences in insulin sensitivity and risk marker due to gender and age in hypertensives. J Hum Hypertens 2000;14:51–6.; Kim HS, Abbasi F, Lamendola C, et al. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. Am J Clin Nutr 2001;74:592–5. 22. Feldstein CA, Akopian M, Renauld A, et al. Insulin resistance and hypertension in postmenopausal women. J Hum Hypertens 2002;16(Suppl 1):S145–50.; Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care 2000;23:801–6. 24. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617–21.; Bolego C, Poli A, Paoletti R. Cardiovascular risk in diabetic women. Curr Atheroscler Rep 2003;5:79–81.; Howard BV, Cowan LD, Go O, et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care 1998;21:1258–65.; Barrett-Connor EL, Cohn B, Wingard D, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991;265:627–631.; Anichkov DA, Maksina AG, Shostak NA. Relationships between erythrocyte membrane properties and components of metabolic syndrome in women. Med Sci Monit 2005;11(4):CR203–210.; Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002;1:1.; Wilson PW, Kannell WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999;159:1104–9.; Staessen J, Bulpit CJ, Fagard R, et al. The influence of menopause on blood pressure. J Hum Hypertens 1989;3:427–33.; Staessen J, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 1997;11:507–14.; Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from Women’s Health Initiative. Hypertension 2000:36:780–9.; Schillaci G, Verdecchia P, Borgioni C, et al. Early cardiac changes after menopause. Hypertension 1998:32:764–9.; Sherwood A, Thurston R, Steffen P, et al. Blunted nighttime blood pressure dipping in postmenopausal women. Am J Hypertens 2001;14:749–54.; Rosental T, Oparil S. Hypertension in women. J Hum Hypertens 2000; 14: 691–704.; Kotchen JM, Kotchen TA. Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies. Curr Hypertens Rep 2003;5:505–12.; Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998;97:2197–201.; Vilecco AS, de Aloyso D, Radi D, et al. Plasma catecholamines in pre- and postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens 1997;11:152–62.; Mercuro G, Podda A, Pitzalis L, et al. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. Am J Cardiol 2000;85(6):787–9.; Vongpatanasin W, Tuncel M, Mansour Y, et al. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001;103:2903–8.; Barbagallo M, Dominguez LJ, Licata G, Resnick LM. Effects of aging on serum ionized and cytosolic free calcium: relation to hypertension and diabetes. Hypertension 1999;34:902–6.; Mercuro G, Zoncu S, Cherchi A, Rosano GM. Can menopause be considered an independent risk factor for cardiovascular disease? Ital Heart J 2001;2(10):719–27.; Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98(8):731–3.; Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65.; Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2005;165(5):500–8.; Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90–119.; Cantatore F, Loverro G, Ingrosso A, et al. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheumatol 1995;14(2):157–60.; Cioffi M, Esposito K, Vietri M, et al. Cytokine pattern in postmenopause. Maturitas 2002;41(3):187–92.; Luyer MDP, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2001;86:3629–34.; Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88(6):2470–8.; Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33.; Gabriel SR, Carmona L, Roque M, et al. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2005;(2):CD002229.; Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799–804.; Sciacqua A, Candigliota M, Ceravolo R, et al. Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care 2003;26:1673–8.; Mostaghel E, Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev 2003;11:4–12.; McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther 2005;7(2):55–61.; Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002;4:464–70.; Esler M, Lux A, Jennings G, et al. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. J Hypertens 2004;22:1529–34.; Penicaud L, Berthault MF, Morin J, et al. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens Suppl 1998;16:S45–9.; Remkova A, Kratochvil'ova H. Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. J Hum Hypertens 2002;16(8):549–55.; Piletz JE, Halbreich U. Imidazoline and alpha(2a)-adrenoceptor binding sites in postmenopausal women before and after estrogen replacement therapy. Biol Psychiatry 2000;48(9):932–9.; Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 2005;21(1):113–9.; https://www.rpcardio.com/jour/article/view/341

الاتاحة: https://www.rpcardio.com/jour/article/view/341
https://doi.org/10.20996/1819-6446-2005-1-1-37-42

المؤلفون: МИЩЕНКО В.Н., НИКИШКОВА И.Н.

مصطلحات موضوعية: "НЕМЫЕ" ИНФАРКТЫ МОЗГА,"SILENT" BRAIN INFARCTIONS,СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА,CARDIOVASCULAR RISK FACTORS,ВОЗРАСТ,AGE,РАСПРОСТРАНЕННОСТЬ,PREVALENCE,"НіМі" іНФАРКТИ МОЗКУ,СЕРЦЕВО-СУДИННі ЧИННИКИ РИЗИКУ,ВіК,ПОШИРЕНіСТЬ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/rasprostranennost-serdechno-sosudistyh-faktorov-riska-u-lits-pozhilogo-vozrasta-s-nemymi-infarktami-mozga
http://cyberleninka.ru/article_covers/16526022.png

المؤلفون: Хуторська, Л. А.

المصدر: Clinical Endocrinology and Endocrine Surgery; No. 4(41) (2012); 41-43 ; Clinical Endocrinology and Endocrine Surgery; № 4(41) (2012); 41-43 ; 2519-2582 ; 1818-1384

مصطلحات موضوعية: type 2 diabetes mellitus, cardiovascular risk factors, treatment, сахарный диабет 2-го типа, середечно-сосудистые факторы риска, лечение

وصف الملف: application/pdf

Relation: http://jcees.endocenter.kiev.ua/article/view/86064/81677; http://jcees.endocenter.kiev.ua/article/view/86064

الاتاحة: http://jcees.endocenter.kiev.ua/article/view/86064
https://doi.org/10.24026/1818-1384.4(41).2012.86064

المؤلفون: ХУТОРСКАЯ Л.А.

مصطلحات موضوعية: САХАРНЫЙ ДИАБЕТ 2-ГО ТИПА,СЕРЕДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА,ЛЕЧЕНИЕ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/analiz-effektivnosti-ambulatornogo-nablyudeniya-bolnyh-saharnym-diabetom-2-go-tipa
http://cyberleninka.ru/article_covers/16976365.png

المؤلفون: Бовтюшко, П., Гришаев, С., Филиппов, А.

مصطلحات موضوعية: АТЕРОСКЛЕРОТИЧЕСКАЯ БЛЯШКА,ОБЩАЯ СОННАЯ АРТЕРИЯ,БЕДРЕННАЯ АРТЕРИЯ,СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА,ТОЛЩИНА ИНТИМА-МЕДИА АРТЕРИИ,АТЕРОСКЛЕРОЗ,ATHEROSCLEROTIC PLAQUE,COMMON CAROTID ARTERY,FEMORAL ARTERY,CARDIOVASCULAR RISK FACTORS,ARTERIAL INTIMA-MEDIA THICKNESS,ATHEROSCLEROSIS

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/ateroskleroticheskaya-blyashka-v-regionarnyh-sosudistyh-basseynah-obschey-sonnoy-i-bedrennoy-arteriy-kak-marker-subklinicheskogo
http://cyberleninka.ru/article_covers/15395037.png

المؤلفون: Ефанов, А., Низамова, Д., Дороднева, Е., Медведева, И., Шалаев, С.

مصطلحات موضوعية: СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА,ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА,ПРОФИЛАКТИКА,ГЕНДЕРНЫЕ РАЗЛИЧИЯ,ПРИВЕРЖЕННОСТЬ ЛЕЧЕНИЮ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/gendernye-razlichiya-v-effektivnosti-korrektsii-faktorov-riska-i-priverzhennosti-priemu-rekomendovannoy-lekarstvennoy-terapii-sredi
http://cyberleninka.ru/article_covers/13923891.png